MPN Workshop of the Carolinas 2025 | Unanswered questions in CMML: timing of treatment initiation to delay progression
In this video, Eric Padron, MD, Moffitt Cancer Center, Tampa, FL, briefly highlights the unanswered questions that need to be addressed in the field of chronic myelomonocytic leukemia (CMML). Dr Padron emphasizes the importance of identifying therapeutic strategies to prevent progression and determining when treatment should be initiated. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
You know, I think there’s, you can distill it to one thing and that’s we need drugs. Our patients need therapies that are effective, that are CMML specific. One of the things that we’re working on in our laboratory and in our clinical work is understanding, you know, if we were to repurpose drugs for myeloproliferative diseases, if we were to study CMML-specific drugs, when should we start the treatment? Because CMML is also unique in the sense that while it is a lethal malignancy, about 70% of people that see me in clinic are clinically asymptomatic...
You know, I think there’s, you can distill it to one thing and that’s we need drugs. Our patients need therapies that are effective, that are CMML specific. One of the things that we’re working on in our laboratory and in our clinical work is understanding, you know, if we were to repurpose drugs for myeloproliferative diseases, if we were to study CMML-specific drugs, when should we start the treatment? Because CMML is also unique in the sense that while it is a lethal malignancy, about 70% of people that see me in clinic are clinically asymptomatic. And so oftentimes those patients are advised to watch and wait. And so are there therapeutic strategies that we can employ early on to prevent them from progressing and having fulminant disease? To me, those are the two main questions we have to address.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
